

Special Issue

State of the Art of Pharmaceutical Research in Brazil

Message from the Guest Editors

Brazil is the seventh largest pharmaceutical market in terms of revenue in the ranking of the 20 main economies in the world. Accounting for approximately 3–4% of this global market, this country is the main player in Latin America. Instead, incremental innovations, such as the development of new formulations or fixed-dose combinations, are made in Brazilian pharmaceuticals due to the high cost of radical innovations regarding new Active Pharmaceutical Ingredients (APIs). The main objective of these research projects is usually to investigate new drugs for the treatment of tropical diseases in order to meet internal public health demands. Another important point that favors the search for new drugs for the treatment of these tropical diseases is the intrinsic knowledge acquired over decades by researchers about diseases, vectors and etiological agents that specifically affect the populations of different regions of the country. In this Special Issue, we cover a variety of the main approaches in pharmaceutical research in Brazil.

Guest Editors

Dr. Nubia Boechat

Departamento de Síntese de Fármacos, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

Dr. Frederico Silva Castelo Branco

Laboratório de Síntese de Fármacos - LASFAR, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Manguinhos, Rio de Janeiro CEP 21041-250, Brazil

Deadline for manuscript submissions

closed (28 February 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/130617

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)